×
MediWound EBIT 2012-2024 | MDWD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
MediWound ebit from 2012 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
MediWound EBIT 2012-2024 | MDWD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
MediWound ebit from 2012 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$87.5B
Takeda Pharmaceutical (TAK)
$47.5B
Merck (MKGAF)
$24.4B
Astellas Pharma (ALPMY)
$22B
Sandoz Group AG (SDZNY)
$17.6B
Summit Therapeutics (SMMT)
$16.8B
United Therapeutics (UTHR)
$15.6B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.2B
Catalent (CTLT)
$10.9B
Revolution Medicines (RVMD)
$7.7B
Orion OYJ (ORINY)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$4.3B
Corcept Therapeutics (CORT)
$4.3B
Dyne Therapeutics (DYN)
$3.7B
PTC Therapeutics (PTCT)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Soleno Therapeutics (SLNO)
$2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Xencor (XNCR)
$1.7B
Harrow (HROW)
$1.6B
Cassava Sciences (SAVA)
$1.5B